低外科风险主动脉瓣狭窄患者TAVR或SAVR术后7年健康状况结局
PARTNER 3试验随机比较低外科风险重度主动脉瓣狭窄患者接受TAVR或SAVR后的健康状况,共943例(TAVR 494例,SAVR 449例)纳入分析。两种治疗均使KCCQ和SF-36评分较基线持续改善至7年;TAVR在1个月时KCCQ-OS显著更高(+16.2分,95%CI 14.3-18.1),2年时仍略高(+1.9分,95%CI 0.2-3.7),3-7年无显著组间差异。7年时两组约60%患者达到优良结局。
要点
- TAVR与SAVR均使低风险主动脉瓣狭窄患者健康状况持续改善至7年。
- TAVR术后1个月健康状况恢复显著优于SAVR,2年后两组趋于相似。
- 7年时两组约60%患者存活且KCCQ-OS≥75且较基线下降<10分。
核心结论
- 低外科风险重度主动脉瓣狭窄患者接受TAVR或SAVR后患者报告的健康状况均显著改善并持续至7年。
- TAVR术后早期恢复更快,但2年后两组健康状况结局相似。
研究设计与样本
- PARTNER 3试验为随机对照试验,将低外科风险重度主动脉瓣狭窄患者1:1随机分配至球囊扩张式瓣膜TAVR或SAVR。
- 分析队列共943例,其中TAVR 494例、SAVR 449例;平均年龄73.5±5.9岁,男性占69.2%,平均STS-PROM 1.9%±0.6%,平均KCCQ-OS评分70.9±20.5。
- 采用KCCQ和SF-36在基线、1个月、6个月及第1至7年每年评估健康状况,使用校正基线的重复测量混合效应模型分析组间差异。
主要发现
- TAVR和SAVR均使KCCQ和SF-36汇总评分较基线显著改善并持续至7年随访。
- TAVR术后1个月KCCQ-OS评分显著高于SAVR,平均治疗差异+16.2分(95%CI 14.3-18.1)。
- 2年时TAVR组KCCQ-OS仍略高于SAVR组,平均差异+1.9分(95%CI 0.2-3.7)。
- 第3至7年两组KCCQ-OS评分无显著组间差异。
- 7年时两组约60%患者达到优良结局(存活、KCCQ-OS≥75且KCCQ-OS较基线下降<10分)。
临床怎么用
- 对于低外科风险重度主动脉瓣狭窄患者,选择TAVR或SAVR均可获得持续至7年的健康状况改善。
- TAVR在术后早期(1个月)的健康状况恢复优势明显,可用于 shared decision-making 中向患者说明早期获益。
- 2年后两种治疗的健康状况结局相似,长期随访中无需因健康状况差异而优先选择某一术式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter aortic valve replacement (TAVR) results in early improvements in health status outcomes relative to surgical aortic valve replacement (SAVR) in low-surgical risk patients with symptomatic severe aortic stenosis. However, long-term data comparing the detailed health status outcomes of these 2 treatments are lacking. OBJECTIVE: The purpose of this study was to compare long-term health status outcomes between TAVR and SAVR in low-risk patients and explore heterogeneity of treatment effect. METHODS: The PARTNER 3 (Placement of Aortic Transcatheter Valves) trial randomized patients with severe aortic stenosis and low surgical risk 1:1 to TAVR with a balloon-expandable valve vs SAVR. Health status was evaluated with the Kansas City Cardiomyopathy Questionnaire (KCCQ) and Short Form-36 Heath Survey at baseline and 1 month, 6 months, and annually from years 1 to 7. Between treatment group differences in health status scores over time were examined with mixed effects models for repeated measures adjusted for baseline. RESULTS: The analytic cohort included 943 patients enrolled in the PARTNER 3 trial who had baseline KCCQ assessments and underwent their assigned procedure (494 TAVR, 449 SAVR; mean age: 73.5 ± 5.9 years; 69.2% men; mean Society of Thoracic Surgeons-Predicted Risk of Mortality: 1.9% ± 0.6%; mean KCCQ-overall summary [KCCQ-OS] score: 70.9 ± 20.5). TAVR and SAVR both resulted in significant improvements in KCCQ and Short Form-36 Heath Survey summary scores relative to baseline through 7-year follow-up. KCCQ-OS scores were substantially higher at 1 month after TAVR vs SAVR (mean treatment difference: +16.2 points; 95% CI: 14.3-18.1) and remained modestly higher through 2 years of follow-up (mean difference at 2 years: +1.9 points; 95% CI: 0.2-3.7), but there were no significant between-group differences in years 3-7. At 7 years, ∼60% of patients in both treatment groups had an excellent outcome (alive, KCCQ-OS ≥75; no KCCQ-OS decline ≥10 from baseline). CONCLUSIONS: Patients with severe aortic stenosis at low surgical risk had substantial improvement in patient-reported health status with either TAVR or SAVR that was sustained through 7 years. Patients had earlier recovery with TAVR, but health status outcomes after 2 years were similar between treatment groups. (PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis; NCT02675114).
引用
- Brener MI, Cohen DJ, Kodali SK, et al. Health Status Outcomes 7 Years After Transcatheter or Surgical Aortic Valve Replacement in Low-Surgical Risk Patients With Aortic Stenosis. J Am Coll Cardiol. 2026. PMID: 42524810. doi:10.1016/j.jacc.2026.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。